Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Xenetic Biosciences, Inc. (XBIO)
|
Add to portfolio |
|
|
|
| Price: |
$1.36
| | Metrics |
| OS: |
1.53
|
M
| |
-35
|
% ROE
|
| Market cap: |
$2.08
|
M
| |
-268
|
% ROIC
|
|
Net cash:
|
$10.7
|
M
| |
$7.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($4.5)
|
M
| |
|
|
|
EBIT
|
($4.5)
|
M
| |
|
|
| EPS |
($0.91)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.7 | 1.2 | 0.4 | 0.0 | 0.0 | 7.6 | 3.0 | 0.0 |
| Revenue growth | 47.1% | 165.6% | 2460.3% | | -100.0% | 152.8% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 39.5 | 0.0 |
| Gross profit | 1.7 | 1.2 | 0.4 | 0.0 | 0.0 | 7.3 | -36.5 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | | 96.6% | -1216.7% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 4.8 | 3.2 | 1.7 | 4.9 | 2.9 | 4.1 | 43.7 | 3.4 |
| General and administrative | 3.7 | 3.7 | 3.4 | 4.7 | 4.4 | 6.8 | 6.7 | 6.4 |
| EBIT | -6.7 | -5.7 | -4.7 | -9.6 | -7.3 | -3.6 | -7.9 | -9.8 |
| EBIT margin | -393.6% | -495.1% | -1074.4% | -56272.4% | | -47.1% | -264.4% | |
| Pre-tax income | -6.6 | -5.6 | -10.9 | -12.8 | -7.3 | -3.6 | -54.2 | -12.5 |
| Income taxes | 0.0 | 0.0 | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -6.6 | -5.6 | -13.8 | -18.1 | -7.3 | -3.6 | -58.2 | -12.5 |
| Net margin | -383.9% | -486.4% | -3161.1% | -105821.0% | | -47.4% | -1941.4% | |
| |
| Diluted EPS | ($0.46) | ($0.55) | ($2.16) | ($6.33) | ($9.66) | ($0.41) | ($7.84) | ($2.96) |
| Shares outstanding (diluted) | 14.2 | 10.3 | 6.4 | 2.9 | 0.8 | 8.7 | 7.4 | 4.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|